Ethical conduct and values of Daiichi Sankyo
Our corporate governance – acting with the highest standards
Promoting an ethical culture is of prime importance to us. We strive to conduct our business in a way that not only adheres to the applicable laws and regulations of the countries where we operate, but that also takes into account social consciousness and makes a strong social contribution. These ethical standards apply, for our employees as well as for our business partners. Our expectations of ethical and compliant behavior from all employees are articulated in the high standards set out by our Codes of Conduct. We also attach great importance to transparent communication. We establish similarly high standards in our Business Partner Code of Conduct.
We are committed to creating value for all our stakeholders, including shareholders, employees, customers, and the communities in which we operate. Our long-term success is dependent on our ability to uphold the highest compliance and ethical standards, and we believe that doing so is key to building trust and maintaining positive relationships. Therefore, our corporate governance invests in promoting an ethical culture, and continuously improving our compliance programs and processes. By doing so, we aim to not only meet our legal and regulatory obligations, but also to demonstrate our commitment to doing business in a responsible and sustainable manner. By following high ethical standards and conducting business with integrity, we believe we can build a sustainable future for our company and the communities in which we operate.
Transparency
Financial transparency
Daiichi Sankyo is committed to bringing pharmaceutical innovation from bench to bedside. Innovation is paramount in all that we do, from pursuing new medicines and new methods of drug discovery and delivery, to achieving excellence throughout our organisation.
Disclosure of payments
Our collaborations with Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) play a vital role in advancing medical innovation, improving clinical practice, and ultimately enhancing patient outcomes.
We engage with Patient Organisations, Patients, Members of the Public, and Journalists as part of our broader commitment to advancing healthcare and supporting the communities we serve.
At Daiichi Sankyo UK, we are committed to maintaining the highest standards of integrity, transparency, and accountability in all our external engagements. We believe that openness is fundamental to building trust and fostering meaningful, responsible relationships across the healthcare ecosystem.
In line with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, we publicly disclose Transfers of Value made to relevant stakeholders. These disclosures provide a clear and accessible view of the nature and scope of our interactions and are published annually, covering the previous three years.
Further information can be found on our Transparency and Disclosure page here
UK/DSC/06/26/0011 - September 2026
